Description:
The purpose of this study is to test see the combined effects of the study drug called
Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor
(GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also
cause side effects.
Title
- Brief Title: A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
- Official Title: Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study
Clinical Trial IDs
- ORG STUDY ID:
16-1643
- NCT ID:
NCT03033303
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Hu3F8 | | Hu3F8/GM-CSF Plus Isotretinoin |
GM-CSF | | Hu3F8/GM-CSF Plus Isotretinoin |
Isotretinoin | | Hu3F8/GM-CSF Plus Isotretinoin |
Purpose
The purpose of this study is to test see the combined effects of the study drug called
Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor
(GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also
cause side effects.
Trial Arms
Name | Type | Description | Interventions |
---|
Hu3F8/GM-CSF Plus Isotretinoin | Experimental | In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF. | |
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of NB as defined by a) histopathology (confirmed by the MSK Department of
Pathology), or b) BM metastases or MIBG-avid lesion(s) plus high urine catecholamine
levels.
- Patients must have high-risk NB (MYCN-amplified stage 2/3/4/4S of any age and
MYCN-nonamplified stage 4 in patients greater than 18 months of age).
- Patients must be in first CR/VGPR
- Patients must have a negative human anti-hu3F8 antibody (HAHA) titer
Exclusion Criteria:
- Existing major organ dysfunction, i.e., renal., cardiac, hepatic, neurologic,
pulmonary, or gastrointestinal toxicity ≥ grade 3, with the exception of hearing loss
and hematologic toxicity.
- Active life-threatening infection.
- Inability to comply with protocol requirements
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | N/A |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | relapse-free survival (RFS) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Patients are considered a response failure under this protocol if progressive disease is evident before two years. Deaths from toxicity attributable to protocol treatment will be counted as events. Patients who withdraw or are lost to followup before two years will be considered as progressions. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
Trial Keywords
- Hu3F8
- GM-CSF
- Isotretinoin
- 16-1643
Last Updated
December 11, 2020